An interventional study of Partial enteral nutrition (PEN) with dairy elimination and Dairy elimination alone in Eosinophilic Esophagitis (EoE), sponsored by Kate Farms Inc. Recruiting at 1 site in United States. Open to participants aged 1 Year to 21 Years. Per ClinicalTrials.gov, last updated 2026-04-16.
Sponsored by Kate Farms Inc · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 165 studies in Eosinophilic Esophagitis with a site in United States — 23 open to participants now, 40 under way, 3 of them phase 3. Eosinophilic Esophagitis · United States.
Among the 165 studies in Eosinophilic Esophagitis with a site in United States, this one is the 55th largest by planned enrollment of the 111 interventional ones that give a count, is one of 5 that started in 2026, is one of 33 with no phase, reaches primary completion later than 28 of the 39 other live ones, and was the 162nd registered.
235 studies on the registry are indexed under Eosinophilic Esophagitis; 53 are open to participants now.
Browse Eosinophilic Esophagitis studies →23 of the 165 studies in Eosinophilic Esophagitis with a site in United States are open now. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States, Mali
Ages 18–65
University of North Carolina, Chapel Hill · Sites in United States
Ages 18–65
Johns Hopkins University · Sites in United States
Ages 5–21
Medical College of Wisconsin · Sites in United States
Ages 18+ · Healthy volunteers
Regeneron Pharmaceuticals · Sites in United States
Ages 6 mo–6 yrs
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 43 Eosinophilic Esophagitis studies recruiting now, 13 (30%) set no upper age limit and 27 (63%) stop at 75 or younger; 27 take children under 18; 7 take healthy volunteers.
This study: 1 Year to 21 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
165 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 38 · Phase 3 26 · Phase 4 10
First in 1996; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 36 is below the median of 42 across 134 interventional studies indexed under Eosinophilic Esophagitis.
Median enrollment 36 across the 111 interventional studies, 80 across the 53 observational. Of the 113 that completed or were terminated, 55 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 165 have an industry lead sponsor. The 10 most frequent:
Kate Farms Inc is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Kate Farms Inc has 1 study filed under Eosinophilic Esophagitis — fewer than ten, so there is no comparison to draw.
10 of the studies in Eosinophilic Esophagitis with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06596252Phase 3Dr. Falk Pharma GmbHOnce Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE | 2026-12 |
| NCT04506593Indiana UniversityIndiana University Gastrointestinal Motility Diagnosis Registry | 2026-11 |
| NCT03312686Indiana UniversityChanges in Esophageal Distensibility With Proton Pump Inhibitors in Patients With Esophageal Eosinophilia: A Pilot Study | 2026-12-31 |
| NCT02008903University of Colorado, DenverEsophageal String Test in Eosinophilic Esophagitis | 2027-01 |
| NCT06598462Uniquity One (UNI)A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis | 2027-04-30 |
Add all 10 to your calendar (.ics) → With an account.
Among the 165 studies in Eosinophilic Esophagitis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to introduce a new dietary therapy for Eosinophilic Esophagitis (EoE) patients by using partial enteral nutrition (PEN) to enhance remission rates and explore how this approach affects immune function, gut microbiota, and environmental toxin exposures.
The purpose of this research project is to offer patients diagnosed with Eosinophilic Esophagitis (EoE) a novel dietary therapy approach which models that of evidence-based dietary therapy used in Crohn's disease and the principles of dietary antigen elimination currently successfully implemented in EoE patients. The study proposes using partial enteral nutrition (PEN) to improve remission rates in EoE patients and investigate the mechanism by which these effects immune dysregulation, microbiota shifts, and through assessment of changes in environmental toxin exposure.
Objectives 1: Determine clinical and endoscopic remission rates, adherence, nutrition, and anthropometric measures in EoE patients prior to and three months after PEN with dairy elimination.
Objectives 2: Investigate immune profiles in EoE patients prior to and three months after PEN with dairy elimination.
Objectives 3: Investigate the microbiota in EoE patients prior to and three months after PEN with dairy elimination.
Objectives 4: Investigate environmental contaminants prior to and three months after PEN with dairy elimination.
It is hypothesized favorable shifts in the microbiota, immune system, and environmental contaminants will be present following three months of PEN in the EoE patient population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
12 participants will be control subjects without diagnosis of EoE
12 subjects will be enrolled in the dairy free diet group.
Other: Dairy elimination alone
12 subjects will be enrolled in the diary free and 50% PEN diet
Other: Partial enteral nutrition (PEN) with dairy elimination
Patients in the PEN with dairy elimination group will receive 50% calories from Kate Farms Standard 1.2 formula and 50% dairy free regular diet.
Participants in this group will be on a dairy-free regular diet alone.
Feasibility of PEN assessed by 3-day diet record
Feasibility and adherence of PEN in EoE patients will be evaluated using 3-day diet records collected at 2 weeks post initiation of the study and at 3 months.
Time frame: 3 months
Tolerability of PEN in EoE patients will be assessed by stool quality evaluated using the Bristol Stool Chart.
Bristol stool chart will be used to assess stool quality at 2 weeks and at month 3.
Time frame: 3 months
Clinical and endoscopic remission rates assessed by mucosal eosinophilia and Eosinophilic Esophagitis Histology Scoring System (EoE-HSS) from GI tissue biopsies
For baseline and three-month tissue collection, GI tissue biopsies will be obtained at the time of clinical endoscopy assess mucosal eosinophilia and EoE-HSS.
Time frame: 3 months
Immune profiles assessed by blood markers
Immune profiles in EoE patients will be assessed by blood markers using CBC with differential, comprehensive metabolic panel, C-Reactive Protein, and Erythrocyte Sedimentation Rate before and after PEN and dairy elimination.
Time frame: 3 months
Microbiota shifts in EoE patients
Microbiota shifts will be assessed from stool metabolomics, urine metabolomics, oral swab microbiome, and esophageal brushing of EoE before and after PEN and dairy free diets.
Time frame: 3 months
Environmental contaminants assessed by blood serum levels
Environmental contaminants assessed by CBC with differential before and after PEN with dairy elimination.
Time frame: 3 months
Nutritional status assessed by 3-day diet record and blood collection
Nutrition status of EoE will be assessed by the collection a 3-day diet record, vitamin D, vitamin B12, iron, total iron binding capacity, and ferritin at baseline and 3 months.
Time frame: 3 months
Growth and development assessed by anthropometric measure
Z-scores for height and weight will be collected at baseline and at 3 months.
Time frame: 3 months
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Dec 2027, 21 months after the start.
Of 24 interventional studies with no phase under Eosinophilic Esophagitis, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 41. This study's planned 21 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kate Farms Inc